IP Library Granted Patent US 12,329,666
Granted Patent B1
US 12,329,666 · App. 18/790,337 · Granted Jun 17, 2025

Intracranial stent and method for intracranial stent

Inventors: Sven Tommy Andersson (Älvsjo Älvsjo, SE); Eamon Oliver Brady (County Galway, IE)
Assignee: CEROFLO LIMITED
A61F2/90A61F2/95A61F2230/001A61F2230/0039A61F2230/0067A61F2230/0069A61F2250/0037A61F2250/0039A61F2250/0098
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,329,666
App. No.
18/790,337
Granted
Jun 17, 2025
Kind
B1
Abstract

An intracranial stent includes a proximal end portion having a first diameter, a distal end portion having a second diameter, and a central portion located between the proximal end portion and the distal end portion, the central portion having a third diameter, the third diameter being less than the first diameter and less than the second diameter. The intracranial stent includes patterns of interstices, interstices in the central portion having areas that are smaller than areas of the interstices in the proximal end portion and in the distal end portion when the intracranial stent is in the expanded state. The intracranial stent has an unexpanded state in which diameters of the proximal end portion, the distal end portion, and the central portion are smaller than the first diameter, the second diameter, and the third diameter, respectively.

Claims (42)

1. An intracranial stent, comprising:

a proximal end portion having a first diameter when the intracranial stent is in an expanded state;

a distal end portion having a second diameter when the intracranial stent is in the expanded state;

a central portion located between the proximal end portion and the distal end portion, the central portion having a third diameter when the intracranial stent is in the expanded state, the third diameter being less than the first diameter and less than the second diameter, wherein the third diameter of the central portion is 25% to 70% of the first diameter of the proximal end portion or 25% to 70% of the second diameter of the distal end portion; and

patterns of interstices being formed in the proximal end portion, in the distal end portion, and in the central portion, the interstices in the central portion having areas that are smaller than respective areas of the interstices in the proximal end portion and in the distal end portion when the intracranial stent is in the expanded state,

the intracranial stent having an unexpanded state in which diameters of the proximal end portion, the distal end portion, and the central portion are smaller than the first diameter, the second diameter, and the third diameter, respectively.

2. The intracranial stent of claim 1 , wherein the proximal end portion and the distal end portion have the same axial length.

3. The intracranial stent of claim 1 , wherein the central portion has a cylindrical shape.

4. The intracranial stent of claim 1 , wherein the central portion has a tapered, hourglass, or conical shape.

5. The intracranial stent of claim 1 , wherein the proximal end portion extends at a non-zero angle with respect to the central portion.

6. The intracranial stent of claim 1 , wherein the interstices are formed by a plurality of struts having widths of less than 80 μm.

7. The intracranial stent of claim 1 , wherein the intracranial stent includes struts that form a plurality of rings, a length of a ring of the intracranial stent being less than 2 mm.

8. An intracranial stent, comprising:

a proximal end portion having a first diameter when the intracranial stent is in an expanded state;

a distal end portion having a second diameter when the intracranial stent is in the expanded state;

a central portion located between the proximal end portion and the distal end portion, the central portion having a third diameter when the intracranial stent is in the expanded state, the third diameter being less than the first diameter and less than the second diameter;

patterns of interstices being formed in the proximal end portion, in the distal end portion, and in the central portion;

a proximal transition portion extending from the proximal end portion to the central portion; and

a distal transition portion extending from the distal end portion to the central portion,

the proximal transition portion having a substantially frustoconical shape, the distal transition portion having a substantially frustoconical shape,

the intracranial stent having an unexpanded state and being self-expanding to the expanded state, and

wherein the stent, when in the unexpanded state, has an external diameter that does not exceed 0.6 mm along an entire length of the intracranial stent.

9. The intracranial stent of claim 8 , wherein the proximal end portion has a substantially cylindrical shape, the distal end portion has a substantially cylindrical shape, and the central portion has a substantially cylindrical shape.

10. The intracranial stent of claim 9 , wherein the central portion has an external diameter of 1 mm to 3 mm.

11. The intracranial stent of claim 8 , wherein the central portion has a curved shape.

12. The intracranial stent of claim 8 , wherein the proximal end portion defines a proximal axis, the distal end portion defines a distal axis, and the central portion defines a central axis, the central axis forming an angle of greater than 0 degrees with the proximal axis.

13. The intracranial stent of claim 8 , wherein the intracranial stent has a braided structure.

14. The intracranial stent of claim 8 , further including interstices formed in the proximal transition portion and in the distal transition portion, interstices of the pattern of interstices in the central portion being smaller than the interstices of the proximal transition portion, the distal transition portion, the proximal end portion, and the distal end portion.

15. The intracranial stent of claim 8 , wherein the proximal transition portion and the distal transition portion each define a cone with a cone angle of approximately 60 degrees to approximately 120 degrees.

16. The intracranial stent of claim 8 , wherein the central portion is constructed to exert a radial force to the stenosis that is greater than a radial force applied with the end-sections to tissue adjacent the stenosis.

17. An intracranial stent, comprising:

a proximal end portion having a first diameter when the intracranial stent is in an expanded state;

a distal end portion having a second diameter when the intracranial stent is in the expanded state;

a central portion located between the proximal end portion and the distal end portion, the central portion having a third diameter when the intracranial stent is in the expanded state, the third diameter being less than the first diameter and less than the second diameter, wherein the central portion forms a wall, the wall of the central portion having a thickness in a range of 0.02 mm to 0.15 mm;

patterns of interstices being formed in the proximal end portion, in the distal end portion, and in the central portion;

a proximal transition portion extending from the proximal end portion to the central portion; and

a distal transition portion extending from the distal end portion to the central portion,

the proximal end portion having a first axial length,

the distal end portion having a second axial length, the first axial length being different from the second axial length, and

the intracranial stent being self-expanding to the expanded state.

18. The intracranial stent of claim 17 , wherein the central portion has an axial length that is different from the first axial length.

19. The intracranial stent of claim 17 , further including a radiopaque marker at a proximal end or at a distal end of the intracranial stent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2025
From: ANDERSON, SVEN TOMMY; BRADY, EAMON OLIVER
To: CEROFLO LIMITED
Reel/Frame 070260/0597 →
Continuity (3)
Continuation 18149830 · Jan 4, 2023
Continuation 17199156 · Mar 11, 2021
Continuation 16760919
References Cited (84)
US 4733665A · Palmaz · 1988 [cited by applicant]
US 5102417A · Palmaz · 1992 [cited by applicant]
US 5725572A · Lam et al. · 1998 [cited by applicant]
US 5741327A · Frantzen · 1998 [cited by applicant]
US 5855600A · Alt · 1999 [cited by applicant]
US 5861027A · Trapp · 1999 [cited by applicant]
US 5922021A · Jang · 1999 [cited by applicant]
US 5938697A · Killion et al. · 1999 [cited by applicant]
US 6039700A · Sauter · 2000 [cited by applicant]
US 6045568A · Igaki · 2000 [cited by examiner]
US 6190406B1 · Duerig et al. · 2001 [cited by applicant]
US 6267783B1 · Letendre et al. · 2001 [cited by applicant]
US 6273910B1 · Limon · 2001 [cited by applicant]
US 6273911B1 · Cox et al. · 2001 [cited by applicant]
US 6348065B1 · Brown et al. · 2002 [cited by applicant]
US 6402777B1 · Globerman et al. · 2002 [cited by applicant]
US 6409754B1 · Smith et al. · 2002 [cited by applicant]
US 6585758B1 · Chouinard · 2003 [cited by examiner]
US 6652579B1 · Cox et al. · 2003 [cited by applicant]
US 6911016B2 · Balzum et al. · 2005 [cited by applicant]
US 6955685B2 · Escamilla et al. · 2005 [cited by applicant]
US 8728611B2 · Becher et al. · 2014 [cited by applicant]
US 9500405B2 · Hace et al. · 2016 [cited by applicant]
US 9775730B1 · Walzman · 2017 [cited by applicant]
US 10064745B2 · Hossainy · 2018 [cited by examiner]
US 11564797B2 · Chin · 2023 [cited by applicant]
US 11819430B2 · Andersson · 2023 [cited by examiner]
US 20010044647A1 · Pinchuk et al. · 2001 [cited by applicant]
US 20020052643A1 · Wholey · 2002 [cited by examiner]
US 20020052648A1 · McGuckin et al. · 2002 [cited by applicant]
US 20020143384A1 · Ozasa · 2002 [cited by examiner]
US 20030074049A1 · Hoganson et al. · 2003 [cited by applicant]
US 20040015229A1 · Fulkerson et al. · 2004 [cited by applicant]
US 20050038503A1 · Greenhalgh et al. · 2005 [cited by applicant]
US 20050055082A1 · Ben Muvhar · 2005 [cited by examiner]
US 20050085923A1 · Levine · 2005 [cited by applicant]
US 20050187609A1 · Brar et al. · 2005 [cited by applicant]
US 20060184238A1 · Kaufmann et al. · 2006 [cited by applicant]
US 20060229711A1 · Yan · 2006 [cited by applicant]
US 20070005122A1 · Inoue · 2007 [cited by examiner]
US 20070179590A1 · Lu et al. · 2007 [cited by applicant]
US 20080132988A1 · Jordan · 2008 [cited by examiner]
US 20100161033A1 · Jantzen et al. · 2010 [cited by applicant]
US 20120083871A1 · Ryan · 2012 [cited by applicant]
US 20120310363A1 · Gill · 2012 [cited by examiner]
US 20120323305A1 · Benary · 2012 [cited by applicant]
US 20130138219A1 · Toomey et al. · 2013 [cited by applicant]
US 20140243950A1 · Weiner · 2014 [cited by examiner]
US 20140330305A1 · Rood et al. · 2014 [cited by applicant]
US 20140350658A1 · Benary et al. · 2014 [cited by applicant]
US 20150265438A1 · Hossainy · 2015 [cited by examiner]
US 20200254228A1 · Taft · 2020 [cited by examiner]
US 20210007869A1 · Crawford · 2021 [cited by examiner]
US 20210196488A1 · Andersson · 2021 [cited by examiner]
US 20230149192A1 · Andersson · 2023 [cited by applicant]
US 20230165586A1 · Ben-Muvhar · 2023 [cited by applicant]
US 20230225866A1 · Chin · 2023 [cited by applicant]
US 20230355413A1 · Garrison · 2023 [cited by examiner]
CN 204655192U · 2015 [cited by applicant]
EP 1255507B1 · 2003 [cited by applicant]
EP 1666003A1 · 2006 [cited by applicant]
EP 1488763B1 · 2007 [cited by applicant]
EP 1362564B1 · 2008 [cited by applicant]
EP 2596762A1 · 2013 [cited by applicant]
EP 3476370B1 · 2023 [cited by applicant]
JP 2003527924A · 2003 [cited by applicant]
JP 2010094510A · 2010 [cited by applicant]
WO 9716113A1 · 1997 [cited by applicant]
WO 9930643A1 · 1999 [cited by applicant]
WO 03028522A2 · 2003 [cited by applicant]
WO 03101343A1 · 2003 [cited by applicant]
WO 2006108065A2 · 2006 [cited by applicant]
WO 2006127765A1 · 2006 [cited by applicant]
WO 2007079153A2 · 2007 [cited by applicant]
WO 2016003470A1 · 2016 [cited by applicant]
WO 2017086239A1 · 2017 [cited by applicant]
Office action for U.S. Appl. No. 16/760,919 dated Apr. 28, 2023 (Year: 2023). [cited by examiner]
Office Action in CN Application No. 2018800711052, dated Nov. 3, 2022. [cited by applicant]
Search Report in CN Application No. 2018800711052, dated Oct. 28, 2022. [cited by applicant]
Office Action in JP Application No. 2020-544117, issued on Aug. 29, 2022 (9 pages). [cited by applicant]
British Search Report for GB1718299.9, dated Apr. 5, 2018. [cited by applicant]
International Search Report for PCT/EP2018/080213, dated Feb. 12, 2019 (PCT/ISA/210). [cited by applicant]
Written Opinion for PCT/EP2018/080213, dated Feb. 12, 2019 (PCT/ISA/237). [cited by applicant]
Notice of Reasons for Rejection in corresponding JP application No. 2020-544117, dated May 29, 2023. [cited by applicant]
Cited By (1)
US 12,575,953